目的 探討腦心通膠囊聯(lián)合貝那普利治療原發(fā)性高血壓的安全性和有效性。方法 選取內(nèi)江市中醫(yī)醫(yī)院2014年12月-2015年12月收治的原發(fā)性高血壓患者161例，隨機(jī)分成對(duì)照組（80例）和治療組（81例）。對(duì)照組患者口服鹽酸貝那普利片，10 mg/d，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上口服腦心通膠囊，2粒/次，3次/d。兩組患者均連續(xù)服用1個(gè)月。比較治療前后兩組患者臨床療效、血壓和血脂變化以及1年內(nèi)并發(fā)癥發(fā)生情況。結(jié)果 治療后，對(duì)照組和治療組的臨床有效率分別為82.50%、97.53%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者收縮壓和舒張壓均明顯降低（P<0.05）；且治療組患者收縮壓和舒張壓下降幅度明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者低密度脂蛋白、三酰甘油和膽固醇水平均明顯降低（P<0.05）；且治療組患者上述血脂降低水平優(yōu)于對(duì)照組（P<0.05）。治療后1年內(nèi)，對(duì)照組患者并發(fā)癥總發(fā)生率為32.50%，顯著高于治療組的13.58%，兩組并發(fā)癥發(fā)生率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間對(duì)照組和治療組的不良反應(yīng)發(fā)生率分別為21.25%、7.41%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 腦心通膠囊聯(lián)合貝那普利治療原發(fā)性高血壓能夠顯著降低血壓水平，同時(shí)可改善患者血脂和并發(fā)癥發(fā)生，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the safety and efficacy of Naoxintong Capsules combined with benazepril in treatment of primary hypertension. Methods Patients (161 cases) with primary hypertension in Neijiang Traditional Chinese Medicine Hospital from December 2014 to December 2015 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/d, once daily. Patients in the treatment group were po administered with Naoxintong Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy, change of blood pressure and blood lipid, and complication occurred within 1 year in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.50% and 97.53%, respectively, and there was difference between two groups (P < 0.05). After treatment, the systolic and diastolic blood pressure in two groups were significantly decreased (P < 0.05). The systolic and diastolic blood pressure in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the low density lipoprotein, triglyceride and cholesterol levels in two groups were significantly decreased (P < 0.05). And the blood lipid level in the treatment group was significantly better than that in the control group (P < 0.05). After treatment for 1 year, complication rate in the control group was 32.50%, which was significantly higher than 13.58% in the treatment group, with significant difference between two groups (P < 0.05). During the treatment, the adverse reaction in the control and treatment groups were 21.25% and 7.41%, respectively, and there was difference between two groups (P < 0.05). Conclusion Naoxintong Capsules combined with benazepril can significantly improve blood pressure, blood lipid and complication in treatment of primary hypertension, which has a certain clinical application value.